Lan Qiaoshuai, Yan Yan, Zhang Guangxu, Xia Shuai, Zhou Jie, Lu Lu, Jiang Shibo
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China.
Curr Res Microb Sci. 2023 Dec 2;6:100208. doi: 10.1016/j.crmicr.2023.100208. eCollection 2024.
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在全球持续传播，这就需要开发新型治疗方法。尽管许多新开发的抗病毒药物和重新利用的抗病毒药物已应用于2019冠状病毒病（COVID-19）的治疗，但显示出令人满意临床疗效的抗病毒药物数量很少。此外，对关注变体（VOCs）敏感性的丧失以及口服生物利用度的缺乏也限制了一些抗病毒药物的临床应用。这些事实提醒我们，要开发出更有效、具有更好药代动力学/药效学特性的广谱抗病毒药物，以对抗SARS-CoV-2及其变体以及其他人类冠状病毒（HCoV）的感染。在本综述中，我们总结了针对SARS-CoV-2及其变体感染的抗病毒药物临床开发的最新进展。
Zotero 插件